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Context: Patients with Addison’s disease (AD) self-report impairment in specific dimensions on
well-being questionnaires. An AD-specific quality-of-life questionnaire (AddiQoL) was developed
to aid evaluation of patients.
Objective: We aimed to translate and determine construct validity, reliability, and concurrent
validity of the AddiQoL questionnaire.
Methods: After translation, the final versions were tested in AD patients from Norway (n 107),
Sweden (n 101), Italy (n 165), Germany (n 200), and Poland (n 50). Construct validity was
examined by exploratory factor analysis and Rasch analysis, aiming at unidimensionality and fit to
the Rasch model. Reliability was determined by Cronbach’s coefficient- and Person separation
index. Longitudinal reliability was tested by differential item functioning in stable patient sub-
groups. Concurrent validity was examined in Norwegian (n 101) and Swedish (n 107) patients.
Results: Exploratory factor analysis and Rasch analysis identified six items with poor psychometric
properties. The 30 remaining items fitted the Raschmodel and proved unidimensional, supported
by appropriate item and person fit residuals and a nonsignificant 2 probability. Crohnbach’s
-coefficient0.93andPerson separation index0.86 indicatehigh reliability. Longitudinal reliability
was excellent. Correlation with Short Form-36 and Psychological General Well-Being Index scores
was high. A shorter subscale comprising eight items also proved valid and reliable. Testing of
AddiQoL-30 in this large patient cohort showed significantly worse scores with increasing age and
inwomencomparedwithmenbutnodifferencebetweenpatientswith isolatedADand thosewith
concomitant diseases.
Conclusion: The validation process resulted in a revised 30-item AddiQoL questionnaire and an
eight-item AddiQoL short version with good psychometric properties and high reliability. (J Clin
Endocrinol Metab 97: 568–576, 2012)
Primary adrenal insufficiency [Addison’s disease (AD)]is a rare chronic disease, treated with glucocorticoid
and mineralocorticoid replacement (1); additional re-
placement of the adrenal androgen dehydroepiandros-
terone is debated (2–5).Novel treatment strategies such as
modified-release hydrocortisone tablets or continuous sc
hydrocortisone infusion are under investigation (6–9).
There is no gold standard for assessment of treatment, but
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a clinical scoring system has been proposed (10). Patient
surveys reproducibly report impairment in particular di-
mensions of general well-being questionnaires (3, 11, 12).
Generic questionnaires have been applied to study differ-
ences between subgroups of patientswithAD (13, 14) and
other autoimmune endocrinopathies (15). However,
questionnaires containing disease-specific items are likely
to be more sensitive to effects that clinicians wish to mon-
itor (16). Recently, the disease-specific quality-of-life
questionnaire (AddiQoL) was developed as an evaluative
tool in AD (17), which might facilitate the detection of
changes in well-being in future clinical trials and during
regular follow-up of patients.
Validity is the process of demonstrating that an instru-
ment quantifies what it seeks to measure and that it is
useful for this purpose. Construct validity aligns a ques-
tionnaire to a theorized underlying trait and involves test-
ing of correlation between the items. Here we used Rasch
analysis to explore the psychometric properties of AddiQoL.
Rasch analysis is a mathematical item response model in-
creasingly used in somatic medicine and endocrinology
and has been used in validation of Quality of Life-Assess-
mentofGrowthHormoneDeficiency inAdults (AGHDA)
(18), Acromegaly Quality of Life Questionnaire (Acro-
QoL) (19), and the disease-specific questionnaire for eval-
uating QoL in Cushings syndrome (CushingQoL) (20).
The objective is to test howwell the observed data fit with
the expectations of the mathematic measurement model
(21, 22).
Reliability implies the degree to which an instrument is
free from random error. The traditional reliability coeffi-
cient (Cronbach’s-) indicates how well an individual
item correlates with the other items in a questionnaire. In
Rasch analysis, the person separation index (PSI) is equiv-
alent to Crohnbach’s- and represents the power of the
construct to discriminate between respondents, giving an
indication of how precisely patients have been spread out
along the continuum (23). Test-retest reliability or repeat-
ability is the correlation between scores from the same
individual assessed on two separate occasions, given that
their clinical condition is stable.
Concurrent validity measures how the questionnaire
performs against a gold standard instrument, usually by
exploringcorrelationofquestionnaire scores.TheAddiQoLis,
to our knowledge, the first disease-specific Health-
Related Quality of Life (HRQoL) questionnaire in AD,
such that no gold standard exists. In other endocrine
disorders, the Short-Form-36 (SF-36) and the Psycho-
logical General Well-Being Index (PGWB) have been
used to validate the AGHDA (24, 25), the AcroQoL
(26), and the CushingQoL questionnaires (20).
Validation of a questionnaire requires responses from
a large number of subjects, which is difficult to achieve
from a single country, for a rare disorder such as AD.
Hence, in the current study, we translated the original
English AddiQoL into Norwegian, Swedish, Italian, Ger-
man, and Polish versions; thesewere administered to large
cohorts of patientswithAD in each country for evaluation
of construct validity and reliability. Test-retest reliability
was tested inpatient subgroups inNorway, Italy, andSwe-
den. Concurrent validity was investigated by examining
correlation between the AddiQoL scores and results of
simultaneously administered SF-36 and PGWB question-
naires inNorway and Sweden.We also sampledAddiQoL
data from a random population group in Norway. The
final revised questionnaire was ultimately used to assess
HRQoL in different subgroups of this large cohort.
Materials and Methods
Design and subjects
First, the AddiQoL was translated from English into Norwe-
gian, Swedish, German, Polish, and Italian versions, following
international recommendations (27). Second, patients with ver-
ified AD were recruited from patient registries or consecutively
from outpatient clinics. The diagnostic criteria for inclusion in
the European AD database (Euradrenal) are one or more of the
following: 1) low serum cortisol and high ACTH, 2) positive
ACTH stimulation test, and/or 3) chronic replacement therapy
with glucocorticoids and fludrocortisone. The patients received
an invitation letter containing study information and AddiQoL;
by returning the precoded questionnaires, they were included
in the study. In addition, patients in Norway and Sweden re-
ceived the SF-36 and the PGWB for analysis of concurrent va-
lidity. There were no exclusion criteria. The AddiQoL subject
codes were used to retrieve patient characteristics such as age,
sex, and concurrent autoimmune diseases from registries or via
an additional precoded registration form. For analysis of longi-
tudinal reliability, a subgroup of at least 20 clinically stable pa-
tients from Norway, Sweden, and Italy completed AddiQoL a
second time, 2–6 wk after the first questionnaire. A random
sample of 2000 persons with even sex, age, and geographical
distribution was drawn from the Norwegian People Registry.
They received a letter with invitation to participate as control
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subjects by returning the completed anonymizedAddiQoLques-
tionnaire, with registration of age and sex only. Third, the re-
sponses from the patients were analyzed by exploratory factor
analysis (EFA) and Rasch analysis for assessment of validity and
reliability and hence for amendment of the questionnaire. The
study was approved by regional ethics committees in each
country.
Translation
The forward translation was performed by a minimum of
three native speakers of the target language, who had good
knowledge of English. Translations were performed locally by
the study group in each country. Their preliminary versionswere
discussed locally by a panel of experts, i.e. clinicians in endocri-
nology, agreeing on versions to be evaluated further. For quality
control, these versions were assessed by two professional trans-
lators (Lionbridge Technologies Inc., Waltham, MA), who eval-
uated the conceptual equivalence with the original, clarity and
use of a familiar register. Thus, two adjusted versions of each
AddiQoL translationwere generated,whichwere reevaluatedby
the study groups in each country, who decided on a final version.
Questionnaires
The original AddiQoL is a 36-item questionnaire; each item
contains six scoring categories. Twenty-five items are negative
HRQoL statements that need to be reversed for questionnaire
scoring; thus, a higher score indicates a higher level of HRQoL.
The questionnaire was developed in the English language and
initial statistical analysis performed in 85 patients form the
United Kingdom (17). The SF-36 is a generic HRQoL question-
naire, widely used and thoroughly validated (28). The SF-36 is
translated into many languages and has been used in previous
studies of HRQoL in AD (11, 12). The PGWB is a validated
22-item generic HRQoL questionnaire that has been translated
into several languages, intended tomeasure the subjective feeling
of psychological well-being (29).
Construct validity and Rasch analysis
The Rasch model rests on the idea that useful measurement
involves examination of only one human attribute at a time (uni-
dimensionality). The model allows quantitative assessment (ad-
ditivity of items) from data that are ordinal, based on logistic
transformation of the item responses (22). First, EFAwas used to
examine dimensionality of AddiQoL. Second, we applied Rasch
analysis [RUMM 2020 software (30)] to further identify and
eliminate items with poor fit to the Rasch model (31).
Overall fit statistics include item-person interaction statistics,
calculated asmean item location andmeanperson location. Both
person fit and item fit is transformed by RUMM to approximate
a Z-score; this represents a standardized normal distribution.
Therefore, if the items and persons fit the model perfectly, the
mean fit residual is expected to be zerowith SD around 1.Overall
fit statistics also includes 2 statistics for item-trait test of fit to
the model. This tests whether the items work as expected at
group level along the range of the scale. A nonsignificant 2
probability implies that the hierarchical ordering of items and
persons do not vary across the range of the scale.
Generally, any item with a fit residual greater than2.5 is a
cause for concern; a high positive item fit residual indicates that
the item does not separate well between high and low person
ability, and ahighnegative item fit residual indicates redundancy
or local dependency (see below) of the item. Other causes of
misfit to the Rasch model are disordered thresholds and differ-
ential item functioning (DIF; item bias). A threshold is the point
at which the probability of endorsing two neighboring response
alternatives is equal; one threshold exists for each transition be-
tween one scoring alternative to the next. To obtain ordered
thresholds, each item and response alternative was assessed and
collapsedor rescoredwhennecessary.DIF analysis explores item
performance and instrument performance across different pa-
tient groups. DIF exists if one patient group scores significantly
different on an item compared with another patient group with
similar overall HRQoL level (21). Here we performed DIF anal-
ysis for patient sex, age, concurrent disease, country, and time
point (for test-retest reliability analysis).
Each item’s difficulty (item location) and eachperson’s ability
(person location) are organized in ordered hierarchies (22, 32).
By plotting item location and person location on the same scale,
the targeting of the items to the sample population can be ex-
plored. A perfect targeting is indicated if average person location
is zero.
Fit to themodel and an absence of a significant pattern among
the fit residuals supports the scale being unidimensional, i.e.
there is only one concept being measured. Local dependency
exists when there is covariance between the response patterns of
items, and this is considered a breach of the strict unidimension-
ality that the Rasch model requires. This can be corrected for by
grouping items with covariance together, i.e. treating the item
group mathematically as a single combined item (33).
Ultimately, if fit to themodel and unidimensionality are pres-
ent, the individual Person location can then be used as a psy-
chometrically valid total score.
Reliability
PSI is calculated as the ratio of true variance to observed
variance and represents theproportionof variance that is not due
to error (23, 32). APSI of 0.85 ormore is generally required if the
scale is to be used on the individual level. For longitudinal reli-
ability, a test-retest DIF analysis was performed for patient sub-
groups with stable clinical condition in Norway, Italy, and Swe-
den over 2- to 6-wk intervals.
Concurrent validity and normative data
AddiQoL scores were compared with SF-36 scores and
PGWB score in Norway and Sweden. Spearman’s rho with two-
tailed significance was calculated for the correlation analysis. A
Mann-WhitneyU test was used to compareNorwegian patients’
AddiQoL scores with AddiQoL results from a random Norwe-
gian population sample. However, because the items are opti-
mized for patients with AD, the comparison of responses be-
tween patients and healthy controls must be interpreted with
caution.ComparisonofAddiQoL-30 and the subsetAddiQoL-8
(see below) scores in different subgroups of patients was per-
formedbymultiple linear regressionanalysiswith sex, age, coun-
try, and comorbidity as independent variables.
Results
Subjects
A total of 615 patients were recruited from Norway
(n  107), Italy (n  157), Germany (n  200), Sweden
570 Øksnes et al. Quality of Life in Addison’s Disease J Clin Endocrinol Metab, February 2012, 97(2):568–576
(n  101), and Poland (n  50). The Polish data were
omitted fromsomeof the analyses due to lownumbers and
missing data. The original U.K. data were also included
in the pooled data analysis. Patient characteristics are
presented in Table 1. Information on patient comor-
bidities was available for Norway, Italy, Germany, and
Sweden. Test-retests were available from clinically sta-
ble patients, on appropriate substitution therapy, in
Norway (n  37), Italy (n  25), and Sweden (n  29).
SF-36 and PGWB scorings were available from Norway
(n  107) and Sweden (n  101), in which the patient
response rates were 65 and 80%, respectively. In the
Norwegian normative sample, 539 of 2000 persons re-
sponded, producing a response rate of 28%. Of the
respondents 54% (283) were female and 56% (300)
were below the age of 50 yr (18–39 yr, n 166; 40–49
yr, n  134; 50–59 yr, n  123; 60 yr, n  107).
Translation and quality of questionnaire responses
Overall, the evaluations from the professional transla-
tors were favorable; mostly minor errors were noted. The
item “I feel lightheaded” proved difficult to translate.
Overall, the rate of missing responses was below 1%.
There was a tendency towardmissing responses on page 2
of the questionnaire. Items regarding sexuality showed the
most missing responses, i.e.“I am satisfied with my sex-
life,” 7%, and“I have lost interest in sex,” 4.9%.Thiswas
not evenly distributed among countries because 22% of
patients in Poland did not score the former, whereas this
figure for Norway was only 0.9% (United Kingdom, 7%;
Italy, 7.3%; Germany, 5.5%; and Sweden, 6.9%).
Construct validity
Initially, the36-itemquestionnaire showedmisfit to the
Rasch model. The EFA identified four subdimensions of
AddiQoL, which we denoted fatigue (8 items), emotions
(8 items), symptoms (11 items), and miscellaneous (sleep,
sexuality, and impact of intercurrent disease, six items)
(for item overview, see Supplemental Table 1, published
on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org). The three items, nocturia,
dry skin, and gaining weight, did not belong to any sub-
dimension and had poor discriminating properties in the
Rasch analysis. Further analysis revealed that the fatigue
domain fitted the model and achieved unidimensionality
in all countries, and no significant DIF was present for
sex, age, or comorbidity. Therefore, the fatigue subscale
was further tested as a potential AddiQoL short version
(AddiQoL-8). The emotions subdimension showed over-
all good fit to the Rasch model, but there was multidi-
mensionality in the Norwegian data. The item, “Emo-
tional stress makes me exhausted,” had high residual
correlation with the item, “I cope well in emotional situ-
ations,” and displayedDIF in the Swedish data; hence, the
former item was discarded. In the symptoms subdimen-
sion, the item, “I have salt cravings,” displayed misfit in
nearly all countries (Fig. 1A), although certainly a clini-
cally relevant item.Eliminationof this item improved fit to
the model, but 2 probability remained significant for
symptoms in the Italian and German data. The miscella-
neous subdimension showed overall good fit and unidi-
mensionality, but the item, “I have lost interest in sex,”
TABLE 1. Patient characteristics
Norway
(n  107)
Italy
(n  157)a
Germany
(n  200)
Sweden
(n  101)
Poland
(n  50)b
Sex
Male (%) 39 (36.4) 54 (34.8) 53 (26.5) 36 (35.6) 10 (20)
Female (%) 68 (63.6) 101 (65.2) 147 (73.5) 65 (64.4) 40 (80)
Age (yr)
18–29 (%) 6 (5.6) 16 (10.5) 15 (7.5) 6 (5.9) NA
30–39 (%) 17 (15.9) 42 (27.5) 35 (17.5) 18 (17.8) NA
40–49 (%) 29 (27.1) 43 (28.1) 58 (29.0) 22 (21.8) NA
50–59 (%) 32 (29.9) 27 (17.6) 42 (21) 27 (26.7) NA
60–69 (%) 22 (20.6) 17 (11.1) 29 (14.5) 17 (16.8) NA
70 (%) 1 (0.9) 8 (5.2) 21 (10.5) 11 (10.9) NA
Comorbidity (autoimmune)
Present (%) 70 (65.4) 106 (68.4) 153 (76.5) 60 (59.4) NA
Thyroid disease (%) 55 (50.9) 83 (52.5) 125 (62.5) 45 (44.6) NA
Type 1 diabetes (%) 13 (12.0) 6 (3.8) 20 (10) 9 (8.9) NA
Other (%)c 33 (30.6) 21 (13.4) 62 (31) 25 (24.8) NA
NA, Not available.
a For Italy, 16 patients were classified as Autoimmune Polyendocrine Syndrome type 2 (APS2); these are included in comorbidities but excluded
from the thyroid and diabetes numbers.
b Data regarding age and comorbidity are missing from Poland and from a few Italian patients (sex, n  2; age, n  4; and comorbidities, n  2).
c Includes celiac disease, hypoparathyroid disease, pernicious anemia, and primary ovarian failure.
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displayed DIF by sex in the Norwegian, Italian, and Ger-
man data and DIF by age in the Italian and German data
(Fig. 1B). Removal of this item improved fit.
Disordered thresholds were present for many items,
indicating that the subjects had difficulties differentiating
between some response alternatives. We found that re-
scoring the original six response alternatives (123456) to
four (122334) by collapsing the scoring categories “a little
of the time”/“some of the time,” “a good bit of the time”/
“most of the time,” “agree”/“slightly agree,” and “dis-
agree”/“slightly disagree” improved fit and produced or-
dered thresholds.
The 30 remaining items, rearranged in the four revised
subdimensions as superitems, fitted the Rasch model; this
was supported by a nonsignificant item-trait interaction
(2  0.56) in the pooled data. Also, this item solution
proved unidimensional. Supplemental Table 2 displays
the overall fit statistics for the pooled data and for indi-
vidual countries.Therewasno significantDIFbetween the
genders and no DIF when comparing the results from pa-
tients with isolated AD with patients with autoimmune
polyendocrine syndromes. Significant
DIF for age was present in the emo-
tions subdimension in the Swedish
and the pooled data. Significant DIF
for country was present in the fatigue,
the symptom, and the miscellaneous
subdimensions. Based on these results,
we elected to go ahead with validation
of the revised 30-item questionnaire
(AddiQoL-30) and the eight-item sub-
set fatigue (AddiQol-8).
Targeting of the items to the total
patient population is shown in Fig. 2.
Mean person location was 0.21, indi-
cating that mean patient score was
slightly higher than the HRQoL level
targeted by themean of the items (set at
zero). Mean person location for indi-
vidual countries was 0.04 (Poland),
0.09 (Germany), 0.14 (United King-
dom), 0.21 (Italy), 0.23 (Norway), and
0.27 (Sweden), indicating good target-
ing in all countries.
Reliability
AddiQol-30 demonstrated good re-
liability as indicated by Cronbach’s-
0.93 and PSI 0.86. PSI for individual
countries are presented in Supplemen-
tal Table 2. For the AddiQoL-8, PSI
ranged from 0.89 to 0.91 in individual
countries, indicating excellent reliabil-
ity as a separate scale. A total of 91 clinically stable pa-
tients from Norway, Sweden, and Italy performed test-
retest 2–6 wk after the first evaluation. Longitudinal
reliability was excellent because no significant DIF be-
tween separate time points was detected.
Concurrent validity, patient scores, and normative
data
Rasch-transformed AddiQoL-30 and AddiQoL-8
scoreswere comparedwithSF-36 scores andPGWBscores
in the Norwegian (n  107) and Swedish (n  101) pa-
tients. Results from the correlation analyses are given in
Table 2. Rasch-transformed scores from all countries are
shown in Fig. 3. Regression analysis adjusting for age, sex,
country, and comorbidity showed that women scored
significantly worse than men (AddiQoL-30, P 0.001;
AddiQoL-8, P 0.001) and demonstrated worse scores with
increasing age (AddiQoL-30, P  0,001; AddiQoL-8, P 
0.001). No statistical difference was found between pa-
tients with isolated AD and those with autoimmune poly-
FIG. 1. A, Fit to the Rasch model for the item, “I have salt cravings.” The gray line depicts
the expected scoring pattern as estimated by the model. The black dots are actual scoring
from groups of patients with similar HRQoL levels (class intervals). The patients with the
highest HRQoL level (far right) scores less than expected, the patients with the lowest HRQoL
level (far left) scores better than expected, i.e. this item does not separate well between high
and low HRQoL. B, DIF sex for the item, “I have lost interest in sex.” The gray line depicts the
expected scoring pattern estimated from the Rasch model. Men score better than expected,
females worse (P  0.01). This item showed similar results for DIF age. Patients younger than
50 yr scored worse than expected, patients older than 50 yr, better than expected (P  0.01).
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endocrine syndromes. AddiQoL raw scores in patients
(median 89, n 99) were significantly lower than in con-
trols in Norway (median 97, n  462; U  14799, z 
5.516, P  0.001, r  0.23).
Discussion
The validation process resulted in a revised 30-item AddiQoL
questionnaire. High reliability, as evidenced by ade-
quate PSI and a high Cronbach’s-, indicates that the
items discriminate well between groups of patients with
different HRQoL levels. The final revised AddiQoL-30
fitted the stringent Rasch model, implying that basic
requirements for a measurement instrument, such as
unidimensionality, order, and additivity, are fulfilled.
This item solution had the best targeting to the patient
sample.
One important aspect of validity is whether individual
items work similarly in different patient subgroups, i.e.
whether item bias exists (34). No significant DIF was
found between patients with isolated
AD and patients with autoimmune
polyendocrine syndromes, and no DIF
by sex remained in AddiQol-30. With
such reassurance thatAddiQoL-30per-
forms equally in these patient groups,
the significantly lower total scores ob-
served in females vs. males likely rep-
resents a true difference. Similarly, the
lack of difference in AddiQol-30 scores
between patients with isolated AD and
those with polyendocrine syndromes is
also reliable. Both findings are consis-
tent with earlier studies using SF-36 in
AD (11, 14). We cannot rule out the
possibility that the observed DIF by
country is due to qualitative differences
of the translations. Thus, if the aim was to study HRQoL
differences between countries, statistical adjustmentof items
with DIF country would be required (35). However, DIF
countrymayhave negligible clinical impact in evaluating the
HRQoL results from a multicenter clinical trial (36).
We demonstrate high correlation between the Ad-
diQoL-30 and AddiQoL-8 scores and SF-36 and PGWB.
For SF-36 the correlationwas highest with the vitality and
general health scales, which were also most affected in
previous studies in AD (3, 11, 12, 14). Normative data are
not essential in the validation of a disease-specific ques-
tionnaire because several of the issues may not be relevant
to healthy subjects. Normative data were collected only
from Norway; the response rate was low, which could
imply selection bias, but the age and sex distribution of
healthy subjects resembled that of the patient group. We
found a statistically significant difference between the pa-
tients and the controls, but the effect size was small. Sev-
eral of the items showed ceiling effects in the controls,
FIG. 2. Person-item targeting for the revised 30-item AddiQoL. The upper half of the figure
displays spread in AddiQoL scores (person location) for all patients. The lower half depicts
item threshold distribution (item location). The item thresholds cover the range of HRQoL
scores obtained by the patients, hereby minimizing the risk of floor and ceiling effects.
TABLE 2. Concurrent validity: correlation between AddiQoL-30 scores and AddiQoL-8 scores with SF-36 and PGWB
scores
Norway (n  107) Sweden (n  101)
AddiQoL-30 AddiQoL-8 AddiQoL-30 AddiQoL-8
SF-36
Physical functioning 0.743 0.745 0.692 0.687
Role physical 0.689 0.729 0.717 0.661
Bodily pain 0.604 0.538 0.637 0.545
General health 0.802 0.775 0.768 0.692
Vitality 0.753 0.748 0.837 0.803
Social functioning 0.685 0.676 0.603 0.585
Role emotional 0.433 0.418 0.466 0.411
Mental health 0.585 0.554 0.724 0.675
PGWB
Total score 0.816 0.797 0.785 0.706
For Spearman’s rho, all correlations were significant below the 0.01 level (two tailed).
J Clin Endocrinol Metab, February 2012, 97(2):568–576 jcem.endojournals.org 573
which underestimates the effect size. Furthermore, com-
parison of patients with healthy controls always implies
some response bias or a response shift due to adaptation
to chronic disease (37).
The results of the Rasch analysis suggest a revised scor-
ing algorithm. The analysis revealed that the six response
categories of each item had to be collapsed into four to
obtain order, additivity, and fit to the model. The unidi-
mensional structure of the rescored AddiQol-30 suggests
that an index based on the algebraic sum of the item (after
reversal of negative items) scoreswill be valid for practical
purposes, for instance, in cross-sectional studies. How-
ever, AddiQoL was developed primarily as an instrument
to evaluate within-individual well-being in clinical trials.
For this purpose, Rasch-transformed person location
scores will be the optimal psychometric solution.
AddiQoL-30 could possibly be further shortened to re-
duce the respondents’ burden. We found that eight of the
items (constituting the fatigue subscale; AddiQoL-8) also
had good psychometric properties and a higher reliability
than AddiQoL-30 and could be useful as a separate short
version of AddiQoL. High reliability and good discrimi-
native questionnaire characteristics usually imply good
evaluative properties. On the other hand, a very high re-
liability coefficient is not necessarily desirable because the
same properties that increase the reliability coefficients
might also reduce ability to detect change (responsiveness)
(38), and the items most sensitive to change might not be
the most well-fitting items (38, 39). Whereas the
AddiQoL-8 contains items related to fatigue/energy level
only, the AddiQoL-30 also includes items concerning
other clinically relevant issues in AD, which might be im-
portant in evaluating HRQoL changes in response to
changes in treatment. This is probably the reason why the
AddiQoL-8 scale did not target the whole patient popu-
lation as well as AddiQoL-30, with a risk of floor and
ceiling effects that might compromise responsiveness.
Hence, further item reduction will be reevaluated after
testing for responsiveness.
In conclusion, the validation process resulted in a re-
vised, 30-item, AddiQoL questionnaire including a sepa-
rate short version that have high internal consistency and
reliability. Its validity as a HRQoL instrument in AD was
further substantiated by high correlation with SF-36 sub-
scales and the PGWB Index. Although further studies are
necessary to examine its responsiveness to changes in
HRQoL over time, this study suggests that the AddiQoL
could become a valuable tool in the assessment of subjec-
tive health status in patients with Addison’s disease.
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Supplementary table1: AddiQoL items 
 
      Items AddiQoL-36 Sub-dimension AddiQoL-30 
  1. I feel good about my health Fatigue  
  2. I can keep going during the day   
     without feeling tired 
Fatigue  
  3. Normal daily activities make me  
     tired 
Fatigue  
  4. I have to struggle to finish jobs Fatigue  
  5. I have to push myself to do things Fatigue  
  6. I lose track of what I want to say Symptom  
  7. I sleep well Miscelleneous  
  8. I feel rested when I wake up in the  
      morning 
Miscelleneous  
  9. I need to get up during the night to  
      pass water 
Did not fit any dimension Eliminated due to misfit 
10. I feel unwell first thing in the  
      morning 
Symptom  
11. I am satisfied with my sex life Miscelleneous  
12. I am relaxed Emotion  
13. I feel low or depressed Emotion  
14. I am irritable Emotion  
15. I find it difficult to think clearly Emotion  
16. I feel lightheaded Symptom  
17. I have salt cravings Symptom Eliminated due to misfit 
18. I sweat for no particular reason Symptom  
19. I get headaches Symptom  
20. I get nauseous Symptom  
21. My joints and/or muscles ache Symptom  
22. I have back pain Symptom  
23. My legs feel weak Symptom  
24. I worry about my health Symptom  
25. My ability to work is limited Fatigue  
26. I can concentrate well Emotion  
27. I am happy Emotion  
28. I feel full of energy Fatigue  
29. I feel physically fit Fatigue  
30. Emotional stress makes me  
      exhausted 
Emotion Eliminated due to item bias 
31. I have lost interest in sex Miscelleneous Eliminated due to item bias 
32. I put on weight easily Did not fit any dimension Eliminated due to misfit 
33. I have dry skin Did not fit any dimension Eliminated due to misfit 
34. I get ill more easily than others Miscelleneous  
35. I take a long time to recover from  
      illnesses 
Miscelleneous  
36. I cope well in emotional situations Emotion  
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